Senate Committee Eyes Contempt Proceedings Against Valeant’s Pearson

Two lawmakers are mulling contempt proceedings against outgoing Valeant CEO J. Michael Pearson after he failed to provide a deposition on Friday as part of an investigation into drug pricing.
Source: Drug Industry Daily